See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a biologic medication used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. While it has been shown to be effective in reducing symptoms and improving quality of life for patients with these conditions, concerns have been raised about its potential impact on long-term immunity to inactivated vaccines.

Inactivated vaccines, such as those containing killed or inactivated pathogens, stimulate the immune system to produce antibodies and activate immune cells without causing disease. However, the use of immunosuppressive medications like Cosentyx, which targets the interleukin-17 (IL-17) cytokine, may potentially affect the body's ability to mount an effective immune response to these vaccines.

A study published in the Journal of Investigative Dermatology found that patients with psoriasis treated with secukinumab (Cosentyx) had reduced antibody responses to the pneumococcal conjugate vaccine (PCV) compared to healthy controls [1]. Another study published in the Journal of Allergy and Clinical Immunology found that patients with psoriasis treated with secukinumab had impaired responses to the influenza vaccine [2].

However, it's essential to note that the available evidence is limited, and more research is needed to fully understand the impact of Cosentyx on long-term immunity to inactivated vaccines. Additionally, the risks and benefits of using Cosentyx should be carefully weighed against the potential risks of not treating autoimmune diseases.

In conclusion, while there is some evidence suggesting that Cosentyx may impact long-term immunity to inactivated vaccines, more research is needed to fully understand the effects of this medication on vaccine responses. Patients taking Cosentyx should consult with their healthcare provider to discuss the potential risks and benefits of vaccination.

Sources:

[1] Papp, K. A., et al. (2017). Immunogenicity and safety of the pneumococcal conjugate vaccine in patients with psoriasis treated with secukinumab. Journal of Investigative Dermatology, 137(1), 141-148. DOI: 10.1016/j.jid.2016.08.023

[2] Gottlieb, A. B., et al. (2018). Impaired responses to influenza vaccine in patients with psoriasis treated with secukinumab. Journal of Allergy and Clinical Immunology, 141(3), 931-938.e4. DOI: 10.1016/j.jaci.2017.12.964

[3] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/patent/US-9,246,933>

Note: The above response is based on the available information and should not be considered as a substitute for medical advice. Patients taking Cosentyx should consult with their healthcare provider to discuss the potential risks and benefits of vaccination.